Mattia Galli, Renzo Laborante, Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Domenico D'Amario, Davide Capodanno, Elena Tremoli, Charles Micheal Gibson, Roxana Mehran, Dominick J Angiolillo
BACKGROUND:  Phase II randomized controlled trials (RCTs) on factor(F)XI inhibitors have shown promising results but they were burdened by low statistical power for clinical outcomes. METHODS:  We performed a systematic review and meta-analysis of RCT comparing FXI inhibitors versus other anticoagulants (enoxaparin or direct oral anticoagulants, DOACs) or versus placebo on top of antiplatelet therapy. RESULTS:  Eight RCTs testing FXI inhibitors (ISIS 416858, osocimab, abelacimab, milvexian, asundexian) and enrolling 9,216 patients were included...
March 24, 2023: Thrombosis and Haemostasis
Tsukasa Osaki, Chikako Yokoyama, Yasuo Magari, Masayoshi Souri, Akitada Ichinose
Autoimmune factor XIII (FXIII) deficiency (AiF13D) is an acquired life-threatening bleeding disorder due to anti-FXIII autoantibodies (autoAbs). We previously established an immunochromatographic test (ICT) for detection of anti-FXIII-A subunit (FXIII-A) autoAbs. Conversely, the detection of anti-FXIII-B subunit (FXIII-B) autoAbs is currently performed in a limited number of medical facilities through time-consuming and expensive laboratory tests, such as dot-blotting analysis and enzyme-linked immunosorbent assay (ELISA)...
March 23, 2023: Thrombosis and Haemostasis
Azita Hajhossein Talasaz, Parham Sadeghipour, Hooman Bakhshandeh, Babak Sharif-Kashani, Farid Rashidi, Mohammad Taghi Beigmohammadi, Keivan Gohari Moghadam, Somayeh Rezaian, Ali Dabbagh, Seyed Hashem Sezavar, Mohsen Farrokhpour, Atefeh Abedini, Rasoul Aliannejad, Taghi Riahi, Mahdi Yadollahzadeh, Somayeh Lookzadeh, Parisa Rezaeifar, Samira Matin, Ooria Tahamtan, Keyhan Mohammadi, Elnaz Zoghi, Hamid Rahmani, Seyed Hossein Hosseini, Seyed Masoud Mousavian, Homa Abri, Pardis Sadeghipour, Elahe Baghizadeh, Farnaz Rafiee, Sepehr Jamalkhani, Ahmad Amin, Bahram Mohebbi, Seyed Ehsan Parhizgar, Mahshid Soleimanzadeh, Maryam Aghakouchakzadeh, Vahid Eslami, Pooya Payandemehr, Hossein Khalili, Hamed Talakoob, Taranom Tojari, Shadi Shafaghi, Sanaz Tabrizi, Hessam Kakavand, Alireza Kashefizadeh, Atabak Najafi, David Jiménez, Aakriti Gupta, Mahesh V Madhavan, Sanjum Sethi, Sahil A Parikh, Manuel Monreal, Naser Hadavand, Alireza Hajighasemi, Khalil Ansarin, Majid Maleki, Saeed Sadeghian, Stefano Barco, Bob Siegerink, Erica Spatz, Gregory Piazza, Ajay J Kirtane, Benjamin W Van Tassell, Gregory Yh Lip, Erik Klok, Samuel Z Goldhaber, Gregg Stone, Harlan Krumholz, Behnood Bikdeli
BACKGROUNDS: In the INSPIRATION-S trial, atorvastatin versus placebo was associated with a non-significant 16% reduction in 30-day composite of venous/arterial thrombosis or death in ICU patients with COVID-19. Thrombo-inflammatory response in COVID-19 may last beyond the first 30 days. METHODS: This article reports the effects of atorvastatin 20 mg daily versus placebo on 90-day clinical and functional outcomes from INSPIRATION-S, a double-blind multicenter randomized trial of adult ICU patients with COVID-19...
March 21, 2023: Thrombosis and Haemostasis
Aaron F J Iding, Bram M M Kremers, Alejandro Pallares Robles, Hugo Ten Cate, Arina Ten Cate
Residual venous obstruction (RVO) is considered a risk factor of recurrence and possibly other clinical outcomes following deep vein thrombosis (DVT). Current guidelines do not support an RVO-tailored duration of anticoagulant therapy; contemporary data of such management strategies are scarce. We aimed to evaluate an RVO-based management strategy and to assess associations of RVO with recurrence, post-thrombotic syndrome (PTS), arterial events and cancer. To gain further insight, D-dimer levels were measured one month after stopping anticoagulant therapy...
March 21, 2023: Thrombosis and Haemostasis
Masayoshi Souri, Chikako Yokoyama, Tsukasa Osaki, Akitada Ichinose
BACKGROUND: Coagulation factor XIII (FXIII) is a proenzyme of plasma transglutaminase. It comprises two catalytic A subunits (FXIII-A) and two carrier B subunits (FXIII-B). We previously reported that alloantibodies against FXIII-B could promote FXIII clearance in a patient with congenital FXIII-B deficiency who had received infusions of plasma-derived human FXIII (A2B2 heterotetramer). OBJECTIVES: We aimed to investigate whether anti-FXIII-B antibodies affect the catalytic function of FXIII...
March 19, 2023: Thrombosis and Haemostasis
Stavros Konstantinides
Non-applicable (Editorial).
March 19, 2023: Thrombosis and Haemostasis
Siyu Jiang, Yingjie Ai, Xiaowen Fan, Xiaoquan Huang, Ling Wu, Liyuan Ni, Feng Li, Shiyao Chen
The aim of this study was to identify the role of FVIII in PVT occurrence in cirrhotic patients with gastroesophageal variceal bleeding. A total of 453 cirrhotic patients with gastroesophageal varices were enrolled. Computer tomography was performed at baseline and patients were divided into the PVT group and non-PVT group (n=131 vs. 322). Individuals without PVT at baseline were followed up for the development of PVT. Time-dependent receiver operating characteristic(ROC) analysis of FVIII for PVT development was performed...
March 13, 2023: Thrombosis and Haemostasis
Cengiz Akbalut, Ryanne Arisz, Constance Baaten, Gaukhar Baildildinova, Aarazo Barakzie, Rupert Bauersachs, Jurriën M Ten Berg, Wout van den Broek, Hetty C de Boer, Vanessa Broker, Richard Buka, Hugo Ten Cate, Arina Ten Cate, Ciro De Luca, Ilaria De Simone, Françoise Dignat-George, Kathleen Freson, Giulia Gazzaniga, Eric van Gorp, Anxhela Habibi, Yvonne M C Henskens, Aaron F J Iding, Abdullah Khan, Gijsje Koenderink, Akhil Konkoth, Romaric Lacroix, Trisha Lahiri, Wilbur Lam, Rachel Lamerton, Roberto Lorusso, Qi Luo, Coen Maas, Owen J T McCarty, Paola van der Meijden, Joost Meijers, Adarsh Mohapatra, Neta Nevo, Alejandro Pallares Robles, Philippe Poncelet, Christoph Reinhardt, Wolfram Ruf, Ronald Saraswat, Claudia Schonichen, Roger E G Schutgens, Paolo Simioni, Stefano Spada, Henri M H Spronk, Karlygash Tazhibayeva, Jecko Thachil, Rocio Vacik-Diaz, Alicia Veninga, Peter Verhamme, Chantal Visser, Steve P Watson, Philip Wenzel, Ruth Willems, Anne Willers, Pengyu Zhang, Konstantinos Zifkos, Anton-Jan van Zonneveld
The 4th Maastricht Consensus Conference on Thrombosis (MCCT), included the following themes: Theme 1: The "coagulome" as a critical driver of cardiovascular disease Blood coagulation proteins also play divergent roles in biology and pathophysiology, related to specific organs, including brain, heart, bone marrow and kidney. Four investigators shared their views on these organ-specific topics. Theme 2: Novel mechanisms of thrombosis Mechanisms linking factor XII to fibrin, including their structural and physical properties, contribute to thrombosis, which is also affected by variation in microbiome status...
March 13, 2023: Thrombosis and Haemostasis
Shinichi Goto, Shinya Goto
No Abstract.
March 13, 2023: Thrombosis and Haemostasis
Tobias Harm, Moritz Frey, Kristina Dittrich, Andreas Goldschmied, Anne-Katrin Rohlfing, Xiaoqing Fu, Adrian Brun, Tatsiana Castor, Dominik Rath, Karin Müller, Michael Lammerhofer, Meinrad Gawaz
BACKGROUND:  Platelets are key players in the pathophysiology of coronary artery disease (CAD) and platelet hyperreactivity leads to increased risk of developing adverse cardiovascular events. Further, significant changes in the platelet lipidome occur in patients with acute coronary syndrome (ACS) and critically regulated lipids lead to platelet hyperresponsiveness. Statin treatment is crucial in the treatment and prevention of patients with CAD by remodeling lipid metabolism...
March 10, 2023: Thrombosis and Haemostasis
Song Hu, Jiang-Shan Tan, Meng-Jin Hu, Ting-Ting Guo, LIyuan Chen, Lu Hua, Jian Cao
BACKGROUND: Diabetes was considered as a risk factor for venous thromboembolism (VTE), but conflicting findings have been reported from observational studies. This study aimed at investigating the causal associations of type 1 and type 2 diabetes with VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE). METHODS: We designed a bidirectional two-sample Mendelian randomization (MR) analysis by using summary-level data from non-overlapped and large genome-wide association studies performed in European individuals...
February 22, 2023: Thrombosis and Haemostasis
Behnood Bikdeli, Ying-Chih Lo, Candrika Khairani, Antoine Bejjani, David Jiménez, Stefano Barco, Shiwani Mahajan, Cesar Caraballo, Eric Secemsky, Erik Klok, Andetta Hunsaker, Ayaz Aghayev, Alfonso Muriel, Yun Wang, Mohamad Hussain, Abena Appah-Sampong, Yuan Lu, Zhenqui Lin, Sanjay Aneja, Rohan Khera, Samuel Z Goldhaber, Li Zhou, Manuel Monreal, Harlan Krumholz, Gregory Piazza
BACKGROUND: Contemporary pulmonary embolism (PE) research relies on data from electronic health records (EHRs) and administrative databases that use International Classification of Diseases (ICD) codes. Natural language processing (NLP) tools can be used for automated chart review and patient identification. However, there remains uncertainty with the validity of ICD-10 codes or NLP algorithms for patient identification. METHODS: The PE-EHR+ study has been designed to validate ICD-10 codes as Principal Discharge Diagnosis, or Secondary Discharge Diagnoses, as well as NLP tools set out in prior studies to identify patients with PE within EHRs...
February 21, 2023: Thrombosis and Haemostasis
Michelle Pradier, Marc A Rodger, Waleed Ghanima, Michael J Kovacs, Sudeep Shivakumar, Susan R Kahn, Per-Morten Sandset, Clive Kearon, Ranjeeta Mallick, Aurélien Delluc
OBJECTIVE: The SOX-PTS, Amin, and Méan models are three different clinical prediction scores stratifying the risk for post-thrombotic syndrome (PTS) development in patients with acute deep vein thrombosis (DVT) of the lower limbs. Herein, we aimed to assess and compare these scores in the same cohort of patients. METHODS: We retrospectively applied the three scores in a cohort of 181 patients (196 limbs) who participated in the SAVER pilot trial for an acute DVT...
February 21, 2023: Thrombosis and Haemostasis
Andrea Pasta, Francesco Calabrese, Edoardo Giovanni Giannini
Not required.
February 20, 2023: Thrombosis and Haemostasis
Natalie J Jooss, Yvonne M C Henskens, Steve P Watson, Richard W Farndale, Meinrad P Gawaz, Martine Jandrot-Perrus, Natalie S Poulter, Johan W M Heemskerk
BACKGROUND:  In secondary cardiovascular disease prevention, treatments blocking platelet-derived secondary mediators pose a risk of bleeding. Pharmacological interference of the interaction of platelets with exposed vascular collagens is an attractive alternative, with clinical trials ongoing. Antagonists of the collagen receptors, glycoprotein VI (GPVI), and integrin α2β1, include recombinant GPVI-Fc dimer construct Revacept, 9O12 mAb based on the GPVI-blocking reagent Glenzocimab, Syk tyrosine-kinase inhibitor PRT-060318, and anti-α2β1 mAb 6F1...
February 17, 2023: Thrombosis and Haemostasis
Alexandre Raynor, Klara Lunte, Mayssa Gaaloul, Amandine Caillault, Fouzia Zouiti, Céline Desconclois, Virginie Planche
No abstract text is available yet for this article.
February 15, 2023: Thrombosis and Haemostasis
Masahiro Yanagisawa, Hyojeong Han, Subhashree Pradhan, Tanvir Khatlani, Deepika Subramanyam, K Vinod Vijayan
February 10, 2023: Thrombosis and Haemostasis
Cecilia Becattini, Giancarlo Agnelli, Aldo Pietro Maggioni, Francesco Dentali, Andrea Fabbri, Iolanda Enea, Fulvio Pomero, Maria Pia Ruggieri, Andrea Di Lenarda, Ludovica Anna Cimini, Giuseppe Pepe, Susanna Cozzio, Donata Lucci, Michele Massimo Gulizia
BACKGROUND: New diagnosis, risk stratification and treatment strategies became recently available for patients with acute pulmonary embolism (PE) leading to changes in clinical practice and potentially influencing short-term patients' outcomes. RESEARCH QUESTION: The COntemporary management of PE (COPE) study is aimed at assessing the contemporary clinical management and outcomes in patients with acute symptomatic PE. Study design and Methods Prospective, non-interventional, multicentre study...
February 9, 2023: Thrombosis and Haemostasis
Benoit Guillet, Abel Hassoun, Bénédicte Wibaut, Annie Harroche, Christine Biron-Andréani, Yohan Repesse, Roseline d'Oiron, Brigitte Tardy, Brigitte Pan Petesch, Pierre Chamouni, Valérie Gay, Marc Fouassier, Claire Pouplard, Cédric Martin, Hasan Catovic, Xavier Delavenne
BACKGROUND:  rVIII-SingleChain is a recombinant factor VIII (FVIII) with increased binding affinity to von Willebrand factor compared with other FVIII products. rVIII-SingleChain is indicated for the treatment and prevention of bleeding episodes in patients with hemophilia A. OBJECTIVES:  To collect real-world evidence data from patients treated with rVIII-SingleChain to confirm the efficacy and safety established in the clinical trial program and carry out a population pharmacokinetic (PK) analysis...
February 9, 2023: Thrombosis and Haemostasis
Chen Huang, Xueping He, Yueyuan Xie, Hanwei Chen, Yufeng Ye, Yi Sun, Rohan Dharmakumar, Robert K Ryu, Debiao Li, Guoxi Xie, Zhaoyang Fan
OBJECTIVES:  Catheter-directed thrombolysis (CDT) is an effective therapy for acute deep vein thrombosis (DVT). However, predicting the CDT outcomes remains elusive. We hypothesized that the thrombus signal on T1-weighted black-blood magnetic resonance (MR) can provide insight into CDT outcomes in acute DVT patients. METHODS:  A total of 117 patients with acute iliofemoral DVT were enrolled for T1-weighted black-blood MR before CDT in this prospective study...
February 8, 2023: Thrombosis and Haemostasis
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.